Background: Hyperlipidemia is a common complication after kidney transplantation. However, there is little long-term data on the efficacy and tolerability of statin therapy in kidney transplant recipients. Methods: We performed a prospective 3-year study to investigate the effects of atorvastatin treatment in 15 hypercholesterolemic stable renal allograft recipients on maintenance immunosuppression with corticosteroid and cyclosporine. Results were compared with data from 15 historical controls matched for baseline hyperlipidemia and renal allograft function who had been treated with simvastatin. Results: Patients in the two treatment groups showed similar baseline characteristics. The average dosages of atorvastatin and simvastatin were 9.25 ( 2.82 mg and 8.38 ( 1.86 mg, respectively. Atorvastatin treatment reduced total cholesterol (TC) by 31.1%, 27.7%, 25.9% and 28.9%, and low-density lipoprotein (LDL) by 43.4%, 37.4%, 36.8% and 41.6%, after 3, 12, 24 and 36 months of treatment, respectively. A significant reduction in triglycerides (TG) was noted after 3 and 9 months, but was not sustained. High-density lipoprotein levels were unaltered. Reductions in TC and LDL after simvastatin treatment appeared less pronounced, although the differences did not reach statistical significance. At last follow-up, 90.9% of atorvastatin-treated patients achieved target LDL of less than 3.4 mmol/L, compared with 78.6% of the simvastatin group. No patients developed adverse reactions including abnormalities in liver enzyme or creatine kinase levels. Acute rejection was not observed, although one patient on simvastatin developed chronic allograft nephropathy. Conclusion: Atorvastatin and simvastatin demonstrated sustained efficacy in reducing the levels of TC and LDL in stable renal allograft recipients. While atorvastatin may be more potent than simvastatin in the treatment of hypercholesterolemia, its TG-lowering effect was not sustained with long-term treatment. The difference in the therapeutic efficacy between the two drugs might have been due to dose rather than to the drugs themselves.
INTRODUCTION
Vascular complications constitute the principal cause of mortality after kidney transplantation, and hyperlipidemia is an important and prevalent contributory factor [1] . Immunosuppressive medications, notably corticosteroids and calcineurin inhibitors, exert adverse effects on the lipid profile [2] . These are confounded by genetic predispositions and, in some patients, suboptimal renal allograft function. It has been reported that renal allograft recipients show increased levels of total cholesterol (TC), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) and triglycerides (TG) [3] [4] [5] . Dietary intervention alone is often inadequate to normalize the lipid profile [6, 7] , and statin therapy is often required [8, 9] .
Despite the established efficacy of statins in the treatment of hyperlipidemia in non-immunosuppressed subjects, long-term data in renal allograft recipients are relatively limited [10] [11] [12] . Confounding factors in kidney transplant recipients include the effects of concomitant medications on lipid metabolism and changes in the dose of immunosuppressive agents with time after transplantation, so that whether short-term beneficial results are sustained with longer follow-up remains to be established. Atorvastatin and simvastatin are both commonly used in the treatment of hypercholesterolemia, and the former has the additional effect of reducing TG level. Previous short-term studies have reported that simvastatin reduces TC and LDL levels in renal allograft recipients by 20-25% and 29%, respectively [13, 14] . This study aimed to determine the long-term outcome of atorvastatin therapy in hypercholesterolemic Chinese renal allograft recipients with stable allograft function, and to compare the results with historical controls with comparable hyperlipidemia who had been treated with simvastatin.
PATIENTS AND METHODS
Renal transplant patients under the care of the Queen Mary Hospital Renal Unit who were receiving maintenance immunosuppression with corticosteroid and cyclosporine (with or without azathioprine), and who had persistent hypercholesterolemia as defined below were included in the study. Other inclusion criteria included: age more than 16 years at the time of transplant, post-transplant time of more than 6 months, and absence of acute rejection in the past 6 months. Patients who had been treated with rapamycin were excluded. Patients with serum creatinine above 350 +mol/L were excluded, and data were censored when serum creatinine reached this level in patients with deteriorating allograft function. Controls were identified retrospectively. They included renal allograft recipients at the same center who were matched on a one-to-one basis with regard to gender, age (within 5 years) and the pattern and severity of hyperlipidemia (difference < 10%), but who had been treated with simvastatin.
Corticosteroid treatment was methylprednisolone 3 mg/kg/day intravenously for 3 days, followed by prednisolone 30 mg/day tapered to 7.5 mg/day after 6 months. Cyclosporine A (Neoral ® ; Novartis, Basel, Switzerland) was started at 0.8 mg/kg/day with target 12-hour trough levels of 250-300 +g/L within the first 3 months, 180-220 +g/L after 6 months, and 100-150 +g/L after 1 year. Azathioprine was started at 2.5 mg/kg/day and tapered to 2 mg/kg/day after 6 months and 1.5 mg/kg/day after 1 year.
Hypercholesterolemia was defined as TC of at least 6.3 mmol/L or LDL of at least 4.2 mmol/L in fasting lipid profiles repeated at least 3 months apart despite dietary modifications [15] . Hypercholesterolemic patients were treated with atorvastatin at a starting dose of 10 mg daily. The following parameters were documented at baseline and then every 3 months, for a follow-up of 36 months: clinical symptoms and signs; blood pressure; fasting lipid profile including TC (upper limit of normal, ULN, 5.2 mmol/L), LDL (ULN, 3.4 mmol/L), high-density lipoprotein (HDL) (lower limit of normal, 1.0 mmol/L) and TG (ULN, 1.7 mmol/L); serum creatinine; 12-hour trough serum cyclosporine; creatine phosphokinase (CPK); alanine aminotransferase; alkaline phosphatase; and a-glutamyl transpeptidase. Patients were instructed to fast for at least 8 hours before blood samples for lipid profile were obtained. The dose of atorvastatin was titrated to achieve LDL levels below 3.4 mmol/L. Statin treatment was withdrawn in patients who developed abnormal levels of liver enzymes or CPK.
Results from the atorvastatin-treated patients were compared with those of hypercholesterolemic renal allograft recipients from the same center, matched on a one-to-one basis with regard to gender, age (within 5 years) and the pattern and severity of hyperlipidemia (difference < 10%), who had been treated with simvastatin (i.e. historical controls).
Statistical analysis
Serial results were compared between patients treated with atorvastatin and historical controls treated with simvastatin. Data analyses were performed using SPSS 10.0 (SPSS Inc, Chicago, IL, USA). The chi-square test, Student's t test, Wilcoxon rank sum test and Pearson's correlation coefficient were used where appropriate. Continuous variables are expressed as mean ( standard deviation unless otherwise stated. A two-tailed p value of less than 0.05 was taken to indicate statistical significance.
RESULTS
The study included 15 hypercholesterolemic patients treated with atorvastatin and 15 simvastatin-treated controls ( Table 1 ). In addition to the characteristics stipulated by matching criteria, the two groups showed similar prevalence rates of diabetes mellitus and the use of `-blockers or diuretics. The causes of primary renal diseases included: immunoglobulin A nephropathy (n = 5), diabetic nephropathy (n = 2), lupus nephritis (n = 1), other forms of chronic glomerulonephritis (n = 19), adult polycystic kidney disease (n = 1), Alport's syndrome (n = 1), and renal tuberculosis (n = 1). The distribution of etiologies was similar in the two groups.
Statin therapy was started at 56.6 ( 31.9 months and 45.8 ( 31.2 months after transplantation in the atorvastatin and simvastatin groups, respectively (p = 0.356). The starting dose of either statin was 10 mg daily in all subjects. Apart from similar lipid profiles at baseline (Table 1) , the two groups also had similar daily doses of prednisolone, cyclosporine concentration, and serum creatinine levels at all study time points (data not shown).
Treatment with atorvastatin resulted in significant and sustained reductions in TC and LDL at all time points compared with baseline ( Table 2 ). After 3, 12, 24 and 36 months of treatment, TC and LDL were reduced by 31.1%, 27.7%, 25.9% and 28.9%, and by 43.4%, 37.4%, 36.8% and 41.6%, respectively (Table  3 ). TG was significantly decreased after 3 and 9 months ( Table 2 ), but this decrease was not sustained. The level of HDL was not altered in a consistent manner over time. Simvastatin treatment resulted in significant reductions in TC and LDL, but the HDL level remained unaltered ( Table 2 ). The reduction in TG barely reached statistical significance after 24 months of simvastatin treatment. The reductions in TC and LDL were more pronounced after treatment with atorvastatin than with simvastatin, although the differences between the two groups did not achieve statistical significance at some study time points ( Table 3) .
The target LDL level (< 3.4 mmol/L) was achieved by 77.8%, 75.0%, 85.7%, 77.8%, 76.9% and 90.9% of patients after treatment with atorvastatin for 3, 6, 9, 
DISCUSSION
Hyperlipidemia is a common complication after kidney transplantation [1] [2] [3] 8, 9] . The prevalence varies with time after transplantation, and up to 38% of patients could be affected within the first 6 months [16] . Commonly observed abnormal lipid profiles include increased TC, LDL, VLDL and TG levels [5] . Immunosuppressive medications such as corticosteroids, cyclosporine and rapamycin are the major factors contributing to hyperlipidemia in kidney transplant recipients [5] . The short-term efficacy of some HMG-CoA reductase inhibitors or fibrates has been reported in the treatment of hyperlipidemia after renal transplantation [13, 17, 18] . In contrast, there is much less data on the long-term results, especially regarding whether the efficacy is sustained, and tolerability of treatment.
Atorvastatin exhibits higher potency than other HMG-CoA reductase inhibitors in lowering cholesterol levels [19] [20] [21] , and its action of lowering TG presents an added advantage in patients with mixed hyperlipidemia [22] . The latter is especially pertinent in renal transplant recipients since the combined use of statin, fibrate and cyclosporine may predispose patients to side effects such as rhabdomyolysis and abnormal liver biochemistry. This TG reduction has been attributed to reduced hepatocyte cholesterol concentration, increased expression of hepatocyte LDL receptors that can bind both VLDL and LDL remnants, and reduced assembly of VLDL [22] . Treatment with atorvastatin has also been associated with improved endothelial function [23] . Moreover, there are emerging data that statins have immunomodulatory properties independent of their lipid-lowering actions, including the reduction of T-cell activation and inflammatory-cell recruitment into atherosclerotic lesions, and inhibition of interferona-induced expression of major histocompatibility complex II on antigen presenting cells [21] . Whether these additional actions modulate long-term renal allograft function or survival remains to be established. An earlier 3-month study reported reductions of TC and LDL by 30% and 42%, respectively, after treatment with atorvastatin, while cerivastatin treatment resulted in corresponding reductions of 32% and 38% [11] . Due to its frequent association with rhabdomyolysis, cerivastatin is seldom used [24] and was withdrawn from the market in 2001. Another study with followup of 1 year compared several statins including atorvastatin [12] . While the results hinted at greater efficacy with atorvastatin, details concerning the study protocol and statistics were not presented. The effect of fluvastatin in renal transplant patients was investigated in another long-term study that showed significant reduction of cardiovascular endpoints and lipid lowering [25] .
In the present series, we chose to examine the longterm results with two commonly prescribed statins, namely simvastatin and atorvastatin. Our data showed that both drugs were effective and well tolerated in kidney transplant recipients. Notably, rhabdomyolysis and deranged liver biochemistry were not observed. On the whole, more than 75% of patients achieved target lipid levels after treatment with atorvastatin or simvastatin, and the results were maintained during long-term follow-up. It is important that the treatment efficacy is sustained, since our study included stable patients who were subject to the lipogenic effects of maintenance immunosuppressive medications on a long-term basis. In this regard, the results showed that the correction of hyperlipidemia by simvastatin and atorvastatin was maintained throughout the 3 years of follow-up. The magnitudes of reductions in TC and LDL levels among our patients are similar to those of other investigations in Caucasian subjects [19, 26, 27] . We noted lower TC and LDL levels with atorvastatin than with simvastatin, although the differences did not reach statistical significance at most study time points, probably due to the small sample size.
The TG data are intriguing. The more prominent TG-lowering effect of atorvastatin compared to other statins is well established in non-transplant subjects. Preliminary data from short-term studies also suggest that atorvastatin is effective in lowering TG levels, but long-term data are lacking [19, 26] . Our results showed that while the TG-lowering effect of atorvastatin may be more pronounced than that of simvastatin within the first year of treatment, it was unsustainable with long-term therapy. Concomitant corticosteroid and cyclosporine treatment might have contributed to differences in the action of atorvastatin in kidney transplant recipients and other subjects. Since LDL was the primary treatment target in the present study, the lack of sustained efficacy on TG might be related to the dose used instead of the drug itself. These observations underscore the importance of further long-term studies with more patients, in view of the emerging association between hypertriglyceridemia and an overall atherogenic lipid profile [3, 28] .
Our results did not show any significant effect of atorvastatin or simvastatin on 12-hour cyclosporine trough level and graft function. It is important to note, however, that there is potentially a bilateral pharmacokinetic interaction between atorvastatin and cyclosporine, resulting in significantly increased HMG-CoA reductase inhibitory activity in patients who are taking atorvastatin and cyclosporine concomitantly [29] . In addition to immunomodulatory and antiinflammatory actions, treatment with HMG-CoA reductase inhibitors has been associated with reduced levels of C-reactive protein and thrombogenicity [21, 23, [30] [31] [32] . Furthermore, it has been demonstrated that hyperlipidemia per se is a non-immunologic risk factor for the development of chronic allograft nephropathy [33] [34] [35] . We, therefore, selected only patients who were receiving the same immunosuppressive regimen, so obviating the confounding effect of different immunosuppressive agents; but whether statins or hyperlipidemia treatment altered the incidence or course of chronic allograft nephropathy requires further investigations.
Since the present study involved use of historical controls, there is a potential difference in the target LDL levels between the cases and controls. In order to circumvent the problem, historical controls were chosen so that the date of starting simvastatin was in the period 1994-2000, after the publication of the National Cholesterol Education Program (NCEP) Panel II recommendations in 1993. Thus, the target LDL level for historical controls was likely to be similar to that for the atorvastatin group, which had target LDL levels based on the NCEP Panel III in 2001. In addition, although a dietary history was lacking, all patients had been advised to follow strict diet restrictions to minimize the effects of differences in dietary intake. Finally, while the lack of potential adverse effects of both statins might have been due to the small sample size, the safety profiles of both drugs are well established.
In conclusion, both simvastatin and atorvastatin demonstrated sustained efficacy in the treatment of hypercholesterolemia in kidney transplant recipients receiving maintenance immunosuppression with prednisolone and cyclosporine. Atorvastatin appeared to be more potent than simvastatin in reducing LDL and TC. However, the TG-lowering effect of atorvastatin may not be sustained with prolonged therapy. The difference in the therapeutic efficacy between the two drugs might have been due to dose rather than to the drugs themselves. Both drugs are safe, and there was no detrimental effect on graft function.
